Halua

Blog

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Coronavirus disease 2019

    Coronavirus disease 2019

    COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

    The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

    COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

    Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

    Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

  • Analyzing Aevo total value locked fluctuations across ERC-20 orderbooks and settlement latency

    Not all regulators accept advanced proofs today. Call patterns also affect gas. Gas costs and user experience also matter. Operational controls matter as much as cryptography. Regulators want suspicious activity reports. Others use bonding curves or time-locked queues to ration exits and preserve validator uptime. Practical approaches include running intra-entity settlement on the rollup with off-chain liquidity arrangements to bridge withdrawal windows, or using bonded relayers to accelerate exits. Telemetry must capture per-chain metrics for CPU, memory, disk I/O, RPC latency, and consensus performance.

    img3

    • On-chain analysis offers a direct window into how market makers move assets and affect total value locked across DeFi protocols.
    • One common pilot connects a retail CBDC ledger to an interbank settlement system.
    • StealthEX swap flows have become a subtle but important indicator for asset movement across chains and for shifts in total value locked in DeFi protocols.
    • Compliance programs and independent audits increase buyer confidence. Confidence intervals and time-weighted averages help risk engines tune margin requirements.
    • Risk controls and simulation are essential. Reward conversion mechanisms should be transparent. Transparent slashing and appeal processes maintain trust and make it easier for the market to price security.
    • The natural tradeoff is that larger hot balances improve user experience and lower withdrawal queues.

    img1

    Ultimately oracle economics and protocol design are tied. Fee rebates tied to staking or ve-like locking models can reduce short-term sell pressure but increase centralization risk if lockup incentives disproportionately favor large holders. With account abstraction, wallets can bundle operations such as swapping, approval, and transfer into a single atomic transaction, which is especially useful when algorithmic stablecoins require on‑chain rebalancing or rebasing steps before a transfer completes. Increase slippage tolerance carefully to see if the route completes, but be aware of the risk of worse execution. Platforms that enable token listings and platforms that offer custodial crypto services face different incentives and constraints, and analyzing Qmall listings alongside Robinhood Crypto custody tradeoffs highlights where market access and custody security collide. Total Value Locked has become the default shorthand for gauging the size and health of DeFi ecosystems, but its application to layer two networks and cross‑chain protocols requires fresh scrutiny. Using testnet orderbooks properly shortens development time and reduces operational risk, but rigorous simulation and cautious staging remain essential before deploying capital.

    1. The API lets you script lookups for contract balances and token ledgers, iterate over known protocol contract addresses, and fetch bonded and locked tokens from staking modules and escrow pallets.
    2. Exchanges list VTHO on orderbooks and peers trade it with spot liquidity and depth. Depth can be thin at extreme prices. Prices vary across exchanges and aggregators. Aggregators that can simulate multi‑hop and multi‑chain sequences reduce surprise.
    3. More capital raises total value locked, or TVL, in the ecosystem. Ecosystem factors matter as much as cryptography. Emerging L3s also tackle extractable value and front-running. Anti-frontrunning and time locks on major changes give the community time to respond.
    4. Teams diversify protocol reserves across chains and instruments, and they use dynamic hedging and on-chain options to protect against correlated crashes, preserving value during periods of systemic stress. Stress tests should combine long delays with liquidity droughts.
    5. My knowledge is current through June 2024, so readers should verify specific developments after that date. Updates refine edge cases in those mechanisms. Mechanisms that integrate social staking help bootstrap new markets.

    Therefore auditors must combine automated heuristics with manual review and conservative language. Phantom users who understand how GMX-derived liquidity behaves within Aevo—its depth, rebalancing rhythm, and fee dynamics—will achieve better execution and risk control. Custody is not neutral for TVL: it shapes where value resides and how that value can be deployed.

    img2

  • How emerging regulations influence sharding implementations and cross-jurisdictional data

    When a market like LBank removes a midcap token, the immediate trading volume often falls sharply. In short, routing intelligence transforms liquidity provision from a scattershot approach into a data‑driven allocation problem. Another frequent problem appears when multiple devices or browser tabs submit transactions in parallel using the same account. Account and address format issues are common. Aggregators run in regional edge clusters. WhiteBIT’s listing policies play a decisive role in shaping how emerging token ecosystems develop. In sum, Fetch.ai’s sharding roadmap, by embracing parallel execution and shard-aware design, can materially raise agent throughput and reduce costs, but the magnitude of improvement hinges on careful shard design, cross-shard protocol efficiency, and complementary off-chain strategies that preserve security while enabling high-frequency agent economies.

    img1

    • Arbitrage in cryptocurrency markets can be adapted to small capital by focusing on emerging exchange pairs where inefficiencies persist. Persistent sell-side pressure is visible as repeated sell transactions from top holders and continuous LP token burns or withdrawals.
    • Proto-danksharding and EIP-4844 introduced blob-carrying transactions that make rollup calldata much cheaper on the base layer. Layer 2 privacy rollups and application-specific chains can host the bulk of computation and state while anchoring proofs to the settlement layer for finality.
    • Messaging layer flaws are equally dangerous: relay corruption, oracle manipulation, replay across chains, faulty light client implementations, and insufficient handling of chain reorganizations can all allow unauthorized minting or double-spend.
    • Any relay that depends on an external oracle needs clear service level agreements and transparent incentives. Incentives are therefore both economic and technical. Technical choices, such as account-based systems or token-based systems, shape how privacy can be delivered.
    • Small improvements in wording and button placement can drastically raise completion rates. Attacks arise when sybil identities, vote buying, or collusion distort decision making. Making such indicators available on-chain removes reliance on centralized reporting and reduces information asymmetry between lead traders and followers.
    • Enable address whitelisting and transaction limits at the protocol or application layer if supported. That combination can widen mainstream adoption without sacrificing the decentralized properties that make blockchain applications valuable. Regular patching policies must be balanced with testing to avoid introducing vulnerabilities into critical signing environments.

    Ultimately the ecosystem faces a policy choice between strict on‑chain enforceability that protects creator rents at the cost of composability, and a more open, low‑friction model that maximizes liquidity but shifts revenue risk back to creators. Many creators want royalties to follow secondary sales automatically. If privacy tools are interposed, the data can become noisy. Educate the integration team about token metadata, contract verification, and recommended gas strategies to ensure smooth user experience and reduce failed transactions that can generate noisy order flow. SLAs should reference applicable custody regulations, data residency constraints, and the legal standing of multi-sig arrangements in relevant jurisdictions.

    img3

    1. Operationally, resilient data pipelines and multi-source oracles are essential.
    2. Custodial providers often need to comply with regulations.
    3. Proto-danksharding and blob-carrying transactions reduced calldata costs, creating immediate gains for rollups, while a phased approach toward full danksharding promises much larger DA bandwidth that many rollups can share.
    4. Financial settlements need strong, quick finality.
    5. It enforces safety margins to reduce liquidation risk.

    Overall inscriptions strengthen provenance by adding immutable anchors. In the end, choose upgrades that match the dApp’s tolerance for risk, need for throughput, and commitment to decentralization. Where composability, decentralization, and simplicity are priorities, investing in optimized L2 primitives or protocol-level scaling may deliver a better return. Return dynamics also differ. Both technologies influence privacy, compliance, and interoperability trade offs. Some implementations add cover traffic and adaptive delays to increase resistance to global passive adversaries. Developers on LUKSO use LSP standards to represent tokens, profiles, and metadata in a consistent way.

    img2